JAK inhibition in the treatment of inflammatory rheumatic diseases
Authors:
Ladislav Šenolt
Authors‘ workplace:
Revmatologický ústav 1. LF UK, Praha
Published in:
Vnitř Lék 2023; 69(3): 181-188
Category:
Review Articles
doi:
https://doi.org/10.36290/vnl.2023.031
Overview
The most common immune-mediated inflammatory rheumatic diseases, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis and have reached significant advances in recent years with the introduction of biological therapies against cytokines and immune cells, but also against intracellular enzymes, specifically Janus kinases (JAKs). Intracellular JAK signalling is activated by binding of various cytokines or growth factors to the respective cellular receptors, allowing the activation of STAT (Signal Transducers and Activators of Transcription) transcription factors and ultimately the transcription of genes with important roles during the innate and adaptive immune response. Four Janus kinases have been described: JAK1, JAK2, JAK3 and tyrosine kinase-2 (TYK2). Four JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) are currently approved for the treatment of rheumatoid arthritis, and some for the treatment of psoriatic arthritis and axial spondyloarthritis. JAK inhibitors have varying selectivity against individual kinases. Some JAK inhibitors are being tested in other rarer systemic connective tissue diseases. The general advantages of JAK inhibitors are oral administration, rapid onset of action, and efficacy in monotherapy. The safety profile of JAK inhibitors compared with biologic therapy appears to be comparable, with a higher incidence of herpes zoster, and an increased incidence of major cardiovascular disease, thromboembolic complications, and cancer in at-risk patients is discussed. The aim of this paper will be to summarize the latest findings on JAK inhibitors in approved indications for the most common rheumatic diseases.
Keywords:
JAK inhibitors – safety profile – immune‑mediated inflammatory rheumatic diseases – intracellular signalling
Sources
1. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
2. Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479.
3. Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205-216.
4. Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. 2019 Aug 30;8:F1000.
5. Briscoe J, Guschin D, Müller M. Signal transduction. Just another signalling pathway. Curr Biol. 1994;4:1033-5.
6. Shuai K, Ziemiecki A, Wilks AF, et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature. 1993;366:580-3.
7. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
8. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862.
9. McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803-816.
10. Tanaka Y, Luo Y, O‘Shea JJ, Nakayamada S. Janus kinase‑targeting therapies in rheumatology: a mechanisms‑based approach. Nat Rev Rheumatol. 2022 Mar;18(3):133-145.
11. Westhovens R. Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology (Oxford). 2019;58(Suppl 1):i27-i33.
12. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i17-i26.
13. Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;8:212595.
14. Šenolt L, Mann H, Závada J, Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. Česká revmatologie. 2017;25(1):3-18.
15. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i17-i26.
16. Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient‑reported outcomes from the randomised phase III ORAL Start trial. RMD Open 2016;2:e000308.
17. Keystone EC, Taylor PC, Tanaka Y, et al. Patient‑reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA‑BEAM study. Ann Rheum Dis 2017;76:1853_61.
18. Rubbert‑Roth A, Enejosa J, Pangan AL, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020 Oct 15;383(16):1511-1521.
19. Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult‑to‑treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61.
20. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‑modifying antirheumatic drugs: 2022 update. Ann Rheum, DiS. 2023;82(1):3-18.
21. Pombo‑Suarez M, Sanchez‑Piedra C, Gómez‑Reino J, et al. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK‑pot collaboration of registries. Ann Rheum, DiS. 2023 Feb;82(2):175-181.
22. Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum, DiS. 2017;76(10):e36.
23. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377(16):1537-1550.
24. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227-1239.
25. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525-1536.
26. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT‑PsA 2. Ann Rheum, DiS. 2020;80(3):312-20.
27. van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic Progression According to Baseline C‑reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J Rheumatol. 2019;46(9):1089-1096.
28. McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non‑biological therapy: 56-week data from the phase 3 SELECT‑PsA 1 study. RMD Open. 2021;7(3):e001838.
29. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum, DiS. 2020;79(6):700-712.
30. Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479
31. Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390- 1399.
32. Deodhar A, Sliwinska‑Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double‑blind, placebo‑controlled study. Ann Rheum, DiS. 2021;80(8):1004-1013.
33. Navarro‑Compán V, Wei JC, Van den Bosch F, et al. Effect of tofacitinib on pain, fatigue, health‑related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double‑blind, placebo‑controlled trial. RMD Open. 2022;8(2):e002253.
34. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT‑AXIS 1): a multicentre, randomised, double‑blind, placebo‑controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117.
35. van der Heijde D, Deodhar A, Maksymowych WP, et al. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double‑blind, placebo‑controlled SELECT‑AXIS 1 study and open‑label extension. RMD Open. 2022;8(2):e002280.
36. Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non‑radiographic axial spondyloarthritis (SELECT‑AXIS 2): a randomised, double‑blind, placebo‑controlled, phase 3 trial. Lancet. 2022;400(10349):369-379.
37. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS‑EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum, DiS. 2023;82(1):19-34.
38. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34-i42.
39. Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021;7(1):e001235.
40. Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 2019;18(7):679–90.
41. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum, DiS. 2021 Feb;80(2):169-175.
42. Ytterberg SR, Bhatt DL, Mikuls TR, et al; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-326.
43. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis Rheumatol. 2019;71(6):892-900.
44. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J; ARTIS study group. Venous thromboembolism with JAK inhibitors and other immune‑modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum, DiS. 2023;82(2):189-197.
45. Benucci M, Bernardini P, Coccia C, et al. JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev. 2023 Jan 14;22(4):103276.
46. Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum, DiS. 2022;81(6):815-822.
47. Frisell T, Bower H, Morin M, et al. ARTIS Study group. Safety of biological and targeted synthetic disease‑modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum, DiS. 2023:ard-2022-223762. doi: 10.1136/ard-2022-223762. Epub ahead of print.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2023 Issue 3
Most read in this issue
- JAK inhibition in the treatment of inflammatory rheumatic diseases
- Differential diagnostics of interstitial lung diseases
- Multimorbidity in nephrotic syndrome
- News in gastroenterology, hepatology and digestive endoscopy